RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $81
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $79 to $81.
RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and raises the price target from $79 to $81.